Hypothesis: Circadian‑Gated Cyclic OSK Induction Amplifies TET2‑Mediated Epigenetic Rejuvenation by Coupling NAD+ Salvage to Demethylation Waves

<p>Partial reprogramming with OSK factors resets epigenetic age before loss of somatic identity, creating a "safe window" for DNA demethylation and TET2‑dependent gene expression [[https://www.liebertpub.com/doi/10.1089/cell.2023.0072]][[https://doi.org/10.1111/acel.12877]]. However, the duration and tissue‑specific dosing of this window remain poorly defined, limiting translation. We hypothesize that aligning cyclic OSK expression with the endogenous circadian rhythm of NAD+ biosynthesis maximizes TET2 activity and extends the safe window without triggering dedifferentiation or tumorigenesis.</p> <p><strong>Mechanistic rationale</strong></p> <ol> <li><strong>Circadian NAD+ oscillations</strong> drive rhythmic activity of sirtuins (SIRT1/6) and PARPs, which consume NAD+ and influence chromatin state [[https://pubmed.ncbi.nlm.nih.gov/30450724/]]. Peaks in NAD+ occur during the early subjective night in mammals, coinciding with heightened TET2 enzymatic efficiency because TET2 requires α‑ketoglutarate and Fe2+, whose availability is modulated by mitochondrial NAD+/NADH ratios.</li> <li><strong>TET2‑dependent demethylation</strong> is most robust when intracellular α‑ketoglutarate is abundant and succinate levels are low, conditions enhanced by SIRT3‑mediated deacetylation of mitochondrial enzymes during NAD+ peaks.</li> <li><strong>OSK‑induced chromatin opening</strong> transiently increases susceptibility to TET2 action. If OSK pulses are delivered when NAD+ (and thus sirtuin/TET2 activity) is maximal, each pulse yields a larger demethylation effect, allowing lower OSK exposure to achieve the same epigenetic age reduction.</li> <li><strong>Feedback limitation</strong>: Sustained high NAD+ also activates PARP1, which consumes NAD+ and can blunt SIRT signaling. Circadian gating prevents chronic PARP activation, preserving NAD+ pools and reducing risk of genomic instability that could amplify premalignant clones.</li> </ol> <p><strong>Testable predictions</strong></p> <ul> <li>In human fibroblast cultures, OSK induction synchronized to the circadian NAD+ peak (e.g., doxycycline administration at ZT12) will produce a greater reduction in epigenetic age clocks (Horvath, Hannum) per unit of OSK exposure compared to arrhythmic or anti‑phase induction, measured after identical total OSK expression time.</li> <li>The extended demethylation will be accompanied by increased 5‑hmC levels and SIRT1/6 activity, detectable via western blot and ELISA, without elevation of pluripotency markers (OCT4, NANOG) beyond baseline.</li> <li>In aged mice, liver‑targeted AAV9‑OSK delivered on a circadian schedule (weekly on/off aligned to dark phase) will yield a longer median lifespan extension (>109%) and lower incidence of hepatic dysplasia than non‑circadian cyclic OSK, while maintaining teratoma‑free status.</li> <li>Pharmacological NAD+ boosting (e.g., NR supplementation) will augment the effect of circadian‑gated OSK, whereas NAD+ depletion (via FK866) will abolish the advantage, confirming NAD+ dependence.</li> </ul> <p><strong>Falsifiability</strong></p> <p>If circadian‑timed OSK fails to produce a superior epigenetic age reduction per dose, or if NAD+ manipulation does not modulate the outcome as predicted, the hypothesis would be refuted. Similarly, observation of increased tumorigenic markers under the circadian regimen would challenge the safety claim.</p> <p><strong>Implications</strong></p> <p>This hypothesis integrates epigenetic reprogramming with metabolic circadian biology, offering a concrete, adjustable protocol to widen the therapeutic window of partial reprogramming. Success would enable lower vector doses, reduce off‑target risks, and accelerate translation toward systemic anti‑aging interventions.</p>